SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| ANGELIQ F-C TABLETS | 1, 2 mg | Film-coated tablet · Oral use | 28 Blister | SAR 46.95 | NCE · Prescription | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| ANGELIQ | 0.25MG;0.5MG; 0.5MG;1MG | tablet · oral | BAYER HLTHCARE | Prescription | 28 Sep 2005 |
| DROSPIRENONE AND ESTRADIOL | 0.5MG;1MG | tablet · oral | NOVAST LABS | Prescription | 28 Oct 2025 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| ANGELIQ | 02268825 | 1.0 MG; 1.0 MG | TABLET · ORAL | BAYER INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | ANGELIQ 0.25 MG-0.5 MG TABLET | $6.36769 | per EA | 23 Sep 2026 |
| US NADAC | ANGELIQ 0.5 MG-1 MG TABLET | $6.36667 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.